This Incredibly Cheap Growth Stock Could Soar 44%, According to Wall Street Analysts
Opera delivered outstanding results recently and its guidance points toward an improvement in its growth.
The stock is cheaply valued, and its earnings growth suggests it is on track to deliver solid gains to investors.
10 stocks we like better than Opera ›
Shares of Opera (NASDAQ: OPRA) have blown hot and cold on the market so far this year, as the company's strong quarterly results have been overshadowed by the broader stock market weakness; however, analysts are expecting shares of the Norway-based web browser maker to reverse the 8% drop they have witnessed so far in 2025 and head higher in the coming year.
Opera stock carries a 12-month price target of $25 as per the seven analysts covering the stock, with all of them having a buy rating. That points toward 44% gains from current levels. There is a good chance that Opera will be able to indeed deliver such solid gains and head higher thanks to its impressive growth and attractive valuation.
Let's look at the reasons why buying Opera stock right now could turn out to be a smart move.
Opera released its first-quarter results on April 28, and the company crushed Wall Street's expectations by a big margin. Its revenue shot up 40% year over year, while adjusted earnings increased by 35%. This marks a significant improvement from the year-ago period when the company reported a 17% jump in revenue and a flat bottom-line performance.
What's more, Opera has raised its full-year revenue growth guidance by three points to 20% to $575 million at the midpoint. The company, which is known for its web and mobile browsers, has been benefiting from the stronger monetization of its properties. Advertisers are now spending more money on the company's Opera Ads platform, which gives them multiple channels to reach its 293 million monthly active users (MAUs) across both mobile and desktop.
From programmatic advertising that uses real-time data to help advertisers buy and serve ads to premium display areas on its web browsers to push notifications and in-app notifications, Opera is trying to entice advertisers by offering multiple ways to display ads. The good part is that this strategy is paying off. Opera's ad revenue shot up an impressive 63% year over year in the previous quarter and accounted for two-thirds of its top line.
Another thing worth noting is that Opera's average revenue per user (ARPU) increased by an impressive 45% year over year in Q1, owing to the terrific growth of the advertising business. Looking ahead, there is a good chance that Opera will be able to win a bigger share of advertisers' wallets as it is integrating agentic artificial intelligence (AI) into its browsers that will perform tasks on users' behalf.
Opera's Browser Operator platform will allow users to shop online, book tickets, look for hotels, and complete other tasks on the web with the help of an AI agent that will take instructions from users before going about its job. This could help Opera strike more advertising deals through preferred partnerships and revenue-sharing models. For instance, the AI agent could direct the user toward a preferred travel booking website for booking tickets or hotels, and Opera could earn a commission out of the transaction.
All this explains why the company is now confident of delivering stronger growth in 2025. Even better, analysts are expecting Opera to maintain a healthy double-digit growth rate for the next couple of years as well.
Consensus estimates are projecting an 18% increase in Opera's earnings this year to $1.14 per share. That's expected to accelerate to 23% next year, which is not surprising considering the stellar improvement in the ARPU that the company clocked last quarter.
With Opera integrating new features, such as AI, into its browsers that could unlock more value for advertisers and encourage them to spend more on its platform, it won't be surprising to see the company's earnings growth accelerating beyond the next couple of years. That's why now would be a good time to buy this tech stock as it is trading at just 18.5 times earnings, a discount to the Nasdaq-100 index's earnings multiple of 31 (using the index as a proxy for tech stocks).
If the market decides to put a higher valuation on Opera because of its improving growth profile and it trades in line with the index's multiple after a year, its stock price could hit $35 (based on the projected earnings estimate for 2025). That would be nearly double the current levels, indicating that Opera has the potential to outpace analysts' one-year price target and skyrocket substantially going forward.
Before you buy stock in Opera, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Opera wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!*
Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
This Incredibly Cheap Growth Stock Could Soar 44%, According to Wall Street Analysts was originally published by The Motley Fool

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Why The 39% Return On Capital At Adobe (NASDAQ:ADBE) Should Have Your Attention
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. So when we looked at the ROCE trend of Adobe (NASDAQ:ADBE) we really liked what we saw. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. Analysts use this formula to calculate it for Adobe: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.39 = US$8.1b ÷ (US$30b - US$9.2b) (Based on the trailing twelve months to February 2025). Thus, Adobe has an ROCE of 39%. In absolute terms that's a great return and it's even better than the Software industry average of 9.5%. See our latest analysis for Adobe Above you can see how the current ROCE for Adobe compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for Adobe . Investors would be pleased with what's happening at Adobe. The numbers show that in the last five years, the returns generated on capital employed have grown considerably to 39%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 30%. The increasing returns on a growing amount of capital is common amongst multi-baggers and that's why we're impressed. All in all, it's terrific to see that Adobe is reaping the rewards from prior investments and is growing its capital base. Since the stock has only returned 5.6% to shareholders over the last five years, the promising fundamentals may not be recognized yet by investors. Given that, we'd look further into this stock in case it has more traits that could make it multiply in the long term. Before jumping to any conclusions though, we need to know what value we're getting for the current share price. That's where you can check out our that compares the share price and estimated value. High returns are a key ingredient to strong performance, so check out our free list ofstocks earning high returns on equity with solid balance sheets. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Investors Will Want Trip.com Group's (NASDAQ:TCOM) Growth In ROCE To Persist
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. So when we looked at Group (NASDAQ:TCOM) and its trend of ROCE, we really liked what we saw. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. To calculate this metric for Group, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.084 = CN¥14b ÷ (CN¥248b - CN¥77b) (Based on the trailing twelve months to March 2025). So, Group has an ROCE of 8.4%. On its own, that's a low figure but it's around the 9.6% average generated by the Hospitality industry. View our latest analysis for Group In the above chart we have measured Group's prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering Group for free. Even though ROCE is still low in absolute terms, it's good to see it's heading in the right direction. The data shows that returns on capital have increased substantially over the last five years to 8.4%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 33%. This can indicate that there's plenty of opportunities to invest capital internally and at ever higher rates, a combination that's common among multi-baggers. A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what Group has. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence. While Group looks impressive, no company is worth an infinite price. The intrinsic value infographic for TCOM helps visualize whether it is currently trading for a fair price. For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press
43 minutes ago
- Associated Press
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 1, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Iovance's growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers. On July 25, 2024, Iovance announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on 1) 'the iCTC completed annual scheduled maintenance in December' and 'capacity was reduced by more than half for about 1 month,' 2) "[l]ower Proleukin sales' than the company expected, and 3) 'the variable pace at which ATCs began treatment patients.' Investors and analysts reacted immediately to Iovance's revelation. The price of Iovance's common stock declined dramatically. From a closing market price of $3.17 per share on May 8, 2025, Iovance's stock price fell to $1.75 per share on May 9, 2025, a decline of about 44.795% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Iovance's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Iovance class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit